A5052437527- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- HER2/EGFR in Cancer Research
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Blood groups and transfusion
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Fungal Plant Pathogen Control
- COVID-19 Clinical Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- Long-Term Effects of COVID-19
- Cytomegalovirus and herpesvirus research
- Silkworms and Sericulture Research
Erasmus MC
2022-2025
Albert Schweitzer Ziekenhuis
2015-2023
Palmetto Hematology Oncology
2019
Hudson Institute
2017-2018
John Wiley & Sons (United States)
2017-2018
ABSTRACT Approximately 40%–60% of patients reaching a stable deep molecular response during TKI treatment will maintain state remission after discontinuation, denoted as treatment‐free (TFR). Depth assessed by BCR::ABL1 digital PCR prior to discontinuation has demonstrated its significance reliable predictive parameter for TFR. A clinically applicable prediction cutoff 0.0023%IS been established and externally validated. In this study, PCR, most sensitive assay kind, was investigated TFR...
Evaluations of the 'real-world' efficacy and safety tyrosine kinase inhibitors in patients with chronic myeloid leukemia are scarce. A nationwide, population-based, registry was analyzed to evaluate (deep) response rates first subsequent treatment lines eligibility for a cessation attempt adults diagnosed between January 2008 April 2013 Netherlands. The covered 457 patients; 434 phase (95%) 15 (3%) advanced disease phase. Seventy-five percent were treated imatinib 25% second-generation...
Not available.
The monitoring of response in chronic myeloid leukemia (CML) is great importance to identify patients failing their treatment order adjust TKI choice and thereby prevent progression advanced stage disease. Cytogenetic has a lower sensitivity, expensive, requires invasive bone marrow sampling. Nevertheless, guidelines continue recommend performing routine cytogenetic assessments, even when adequate molecular diagnostics are available.In population-based registry newly diagnosed CML the...
Acquired missense mutations in the BCR::ABL1 kinase domain (KD) may cause tyrosine inhibitor (TKI) treatment failure. Based on mutation-specific vitro derived IC50-values, alternative TKI be selected. We assessed clinical practice of KD mutation testing, response relation to and outcome tested patients.Patients from six Dutch CML reference centers a national registry were included once mutational analysis was performed. Reasons for testing categorized as suboptimal response, primary or...
Patients with chronic myeloid leukemia (CML) in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment without relapse. The present study aims to gain insight into the views of CML patients on TKI discontinuation and identify factors that are associated their willingness treatment. A cross-sectional study, among adult Dutch was conducted assess benefits concerns about discontinuation. total 185 participated whom 76% were willing TKI-treatment. considered absence...
Suboptimal guideline adherence in chronic myeloid leukemia (CML) care is associated with worse treatment outcomes. Current study focused on to seven quality indicators (QIs) based the European Leukemia Network (one diagnostic, one therapeutic, and five monitoring indicators). Data were obtained from population-based registries Netherlands of 405 newly diagnosed phase CML patients between January 2008 April 2013. Compliance rates regarding diagnostic therapeutic indicator 83% 78%,...